<DOC>
	<DOCNO>NCT02403869</DOCNO>
	<brief_summary>Post-authorization , prospective follow-up , multi-centre , national study estimate definitive deterioration quality life patient metastatic breast cancer treat second-line monochemotherapy .</brief_summary>
	<brief_title>Quality Life Metastatic Breast Cancer ( MBC ) Patients Second Line Monochemotherapy</brief_title>
	<detailed_description>Post-authorization , prospective , multi-centre study Metastatic Breast Cancer patient treat second-line monochemotherapy . A total 200 patient expect recruit 32 Spanish site . In study result perceive patient compile assess overall Quality Life ( QoL ) MBC patient treat second-line monochemotherapy , use EORTC QLQ-C30 questionnaire ( European Organization Research Treatment Cancer Quality Life Questionnaire ) modules EORTC QLQ-BR23 ( EORTC Breast Cancer specific ) EORTC QLQ-CIPN20 ( EORTC Chemotherapy-Induced Peripheral Neuropathy ) . Patients evaluate time acceptance participate study signing inform consent track every three month treatment second-line monochemotherapy , coincide routine assessment within normal clinical practice . When patient completes treatment second-line chemotherapy he/she enter post-treatment period , follow-up six 12 month completion treatment . Also , patient follow assess survival end study ( 30 month enrolment last patient study ) . Follow-up time establish base median survival patient MBC</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients give write informed consent . Patients metastatic breast cancer start treatment secondline monochemotherapy . Patients sexes , least 18 year age race . Patients life expectancy longer equal 12 week . Patients histological cytological diagnosis Her2/neu negative breast adenocarcinoma . Patients ability enough understand questionnaire . Pregnant lactating woman . Patients treat chemotherapy last three week Patients refuse participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>second line</keyword>
	<keyword>treatment</keyword>
	<keyword>Her 2 negative</keyword>
</DOC>